Bioma secures R$15 million investment from Angra Partners

Bioma, a Brazilian healthtech specializing in genomic and microbiota testing, has raised R$15 million from the Inova Empresa fund, managed by Angra Partners with Finep as its sole investor. With this deal, the fund becomes a minority shareholder and gains a seat on Bioma’s board of directors.

Expanding access to genomic testing in Brazil

Bioma operates in a segment still little explored among Brazilian healthtechs, offering genomic and microbiota tests applied to oncology, fertility, pharmacogenetics, neuropsychiatry, and rare diseases. Traditionally, these tests are either conducted abroad or by large healthcare groups within the country.

According to Alberto Güth, founding partner of Angra Partners and manager of the Inova Fund, Bioma stood out in a highly competitive process.

“We evaluated many companies in the healthcare sector before choosing Bioma. The company brings together attributes not easily found in a single asset: proprietary technology, profitable operations, a scalable business model, and a clear mission to positively impact access to quality healthcare in Brazil,” said Güth.

This marks Angra’s first investment in a healthcare company.

A proven founder and strong technical team

Founded by biomedical scientist Rafael Malagoli, who previously built and sold a company to São Marcos laboratories (part of the Dasa group), Bioma has already conducted over 30,000 tests in its own laboratory.

Its team includes master’s and PhD-level experts in genetics, working to develop international-standard protocols and local technology aimed at reducing costs and accelerating adoption of genetic testing in Brazil. The new capital will support Bioma’s R&D investments and help increase awareness of its solutions among medical professionals.

Scaling innovation with governance

Bioma’s genetic testing goes beyond traditional blood tests, analyzing more than 90 items from a single sample, a business model with significant scalability potential.

Murillo Vianna, Angra partner leading the venture capital team and now joining Bioma’s board, explained:

“We will help strengthen the company’s governance to ensure its expansion remains solid.”

The R$200 million Inova Fund plans to make one more investment this year and another five in 2026. According to Güth, their strategy is clear:

“We don’t invest in PowerPoints. We invest in companies with at least R$16 million in annual revenue.”

With the backing of Angra Partners and the Inova Fund, Bioma is positioned to accelerate innovation in genetic testing and expand its role as a key player in Brazil’s healthtech landscape. This investment marks a pivotal step in making advanced genomic solutions more accessible and impactful for patients across the country.